Loading Events
  • This event has passed.

Roundup of J.P. Morgan’s Annual Healthcare Conference 2020


Biotech Finances and Neighborhood are pleased to invite you to the 3rd edition of the Roundup of J.P. Morgan’s Annual Healthcare Conference in the prestigious setting of the Neighborhood, VCLS’s Innovation Center.

Back from the 37th JP Morgan Healthcare Conference in San Francisco, the editorial staff of Biotech Finances, the only French-speaking professional media company that has attended this event for 3 years offers you:

Roundtable talks on “prospective biotechs 2020”  with key industrial and financial players at this major annual meeting, which sets out the year’s main trends in financing and development of the sector.

Event language: French

About the Speakers :

Cedric Moreau
Partner at Sofinnova Partners
Cedric joined Sofinnova Partners in June 2018 and brings 18 years of experience in life sciences investment banking. Cedric joined from Oddo BHF where he was Managing Director and Head of Healthcare at the Corporate Finance department. In 2017, Oddo BHF was top ranked in the European biotech equity capital market deals league tables.


Sylvain Gariel
Sylvain Gariel is co-founder and COO at DNA Script
Graduated from l’Ecole des Mines en France, Sylvain Gariel coo-founded DNA Script in 2014 along with Thomas Ybert. DNA Script is the world leader and pioneer in enzymatic DNA synthesis. Overcoming current inefficiencies of chemical synthetic DNA production, DNA Script’s technology enables affordable, rapid, high-quality and high throughput production of synthetic biology tools.


Stéphane Piat
Chief Executive Officer & Director at Carmat
Stéphane Piat is an acknowledged specialist in the medical device business, particularly in the field of cardiology. He joined Carmat as Chief Executive Officer in September 2016.


Christine Placet
Christine PLACET joined HORAMA as CEO in early 2016. She previously served as CFO at Trophos from to 2004 until 2012, when she became CEO. During this time Trophos developed an innovative medicinal product for the treatment of spinal muscular atrophy, a rare and currently incurable disease. After obtaining promising results in a Phase II/III trial, the company was bought by Roche Pharmaceuticals in early 2015.